Investors

SEC Filings

SEC Filings

Filing date	Form	Description	View
June 1, 2021	8-K	Report of unscheduled material events or corporate event	0001193125-21-177692.pdf 0001193125-21-177692.rtf 0001193125-21-177692.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 10, 2021	8-K	Report of unscheduled material events or corporate event	0001193125-21-155701.pdf 0001193125-21-155701.rtf 0001193125-21-155701.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 10, 2021	10-Q	Quarterly report which provides a continuing view of a company's financial position	0001628280-21-009696.pdf 0001628280-21-009696.rtf 0001628280-21-009696.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
April 22, 2021	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	0001193125-21-126686.pdf 0001193125-21-126686.rtf 0001193125-21-126686.xls View HTML
April 22, 2021	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-21-126697.pdf 0001193125-21-126697.rtf 0001193125-21-126697.xls View HTML
April 1, 2021	4	Statement of changes in beneficial ownership of securities	0001562180-21-002541.pdf 0001562180-21-002541.rtf 0001562180-21-002541.xls View HTML
April 1, 2021	4	Statement of changes in beneficial ownership of securities	0001562180-21-002539.pdf 0001562180-21-002539.rtf 0001562180-21-002539.xls View HTML
April 1, 2021	4	Statement of changes in beneficial ownership of securities	0001562180-21-002540.pdf 0001562180-21-002540.rtf 0001562180-21-002540.xls View HTML
April 1, 2021	4	Statement of changes in beneficial ownership of securities	0001562180-21-002542.pdf 0001562180-21-002542.rtf 0001562180-21-002542.xls View HTML
April 1, 2021	4	Statement of changes in beneficial ownership of securities	0001562180-21-002544.pdf 0001562180-21-002544.rtf 0001562180-21-002544.xls View HTML

Data provided by Kaleidoscope.

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax